You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,119,791

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,119,791 protect, and when does it expire?

Patent 9,119,791 protects OXTELLAR XR and is included in one NDA.

This patent has fourteen patent family members in ten countries.

Summary for Patent: 9,119,791

Patent landscape, scope, and claims:

Title:	Modified release preparations containing oxcarbazepine and derivatives thereof
Abstract:	Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Inventor(s):	Bhatt; Padmanabh P. (Rockville, MD), Kidane; Argaw (Montgomery Village, MD), Edwards; Kevin (Lovettsville, VA)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	14/445,233
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,119,791
Patent Claim Types: see list of patent claims	Use; Formulation; Composition; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,119,791

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-001	Oct 19, 2012	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Subscribe
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-002	Oct 19, 2012	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Subscribe
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-003	Oct 19, 2012	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,119,791

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E496623	⤷ Subscribe
Australia	2007242984	⤷ Subscribe
Canada	2597740	⤷ Subscribe
China	101489560	⤷ Subscribe
Germany	602007012236	⤷ Subscribe
European Patent Office	2026815	⤷ Subscribe
European Patent Office	2359830	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.